Finn Wisl°ff

Author network for Finn Wisl°ff by COREMINE medical

Publications 2011

Kvam AK, Fayers PM, Wisloff F (2011)
Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma
Eur J Haematol, 87 (4), 330-7
PubMed 21668504

Publications 2010

Gimsing P, Carlson K, Turesson I, Fayers P, Waage A, Vangsted A, Mylin A, Gluud C, Juliusson G, Gregersen H, Hjorth-Hansen H, Nesthus I, Dahl IM, Westin J, Nielsen JL, Knudsen LM, Ahlberg L, Hjorth M, Abildgaard N, Andersen NF, Linder O, Wisl°ff F (2010)
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial
Lancet Oncol, 11 (10), 973-82
PubMed 20863761

Kvam AK, Wisl°ff F, Fayers PM (2010)
Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma
Health Qual Life Outcomes, 8, 79
PubMed 20678240

Smeland EB, Vartdal F, Wisl°ff F (2010)
[Leadership and academic competence]
Tidsskr Nor Laegeforen, 130 (6), 591
PubMed 20348994

Smeland EB, Vartdal F, Wisl°ff F (2010)
[Close cooperation, but not oversteering]
Tidsskr Nor Laegeforen, 130 (6), 590-1
PubMed 20348990

Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bj÷rkstrand B, Carlson K, Dahl IM, Forsberg K, Gulbrandsen N, Haukňs E, Hjertner O, Hjorth M, Karlsson T, Knudsen LM, Nielsen JL, Linder O, Mellqvist UH, Nesthus I, Rolke J, Strandberg M, S°rb° JH, Wisl°ff F, Juliusson G, Turesson I et al. (2010)
Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma
Blood, 116 (9), 1405-12
PubMed 20448107

Publications 2009

Iversen PO, Wisl°ff F, Gulbrandsen N (2009)
Reduced nutritional status among multiple myeloma patients during treatment with high-dose chemotherapy and autologous stem cell support
Clin Nutr, 29 (4), 488-91
PubMed 20044183

Kvam AK, Fayers P, Hjermstad M, Gulbrandsen N, Wisloff F (2009)
Health-related quality of life assessment in randomised controlled trials in multiple myeloma: a critical review of methodology and impact on treatment recommendations
Eur J Haematol, 83 (4), 279-89
PubMed 19558508

Kvam AK, Fayers P, Wisloff F (2009)
What changes in health-related quality of life matter to multiple myeloma patients? A prospective study
Eur J Haematol, 84 (4), 345-53
PubMed 20041946

Publications 2008

Benestad HB, Wisl°ff F (2008)
[Research ethics and University of Oslo]
Tidsskr Nor Laegeforen, 128 (15), 1683-4
PubMed 18704143

Iversen PO, Ukrainchenko E, Afanasyev B, Hulbekkmo K, Choukah A, Gulbrandsen N, Wisl°ff F, Tangen JM (2008)
Impaired nutritional status during intensive chemotherapy in Russian and Norwegian cohorts with acute myeloid leukemia
Leuk Lymphoma, 49 (10), 1916-24
PubMed 18949615

Aasbrenn M, Langmark F, Wisl°ff F (2008)
[Is registration of multiple myeloma in the Norwegian Cancer Registry good enough?]
Tidsskr Nor Laegeforen, 128 (23), 2712-4
PubMed 19079417

Publications 2007

Cocks K, Cohen D, Wisl°ff F, Sezer O, Lee S, Hippe E, Gimsing P, Turesson I, Hajek R, Smith A, Graham L, Phillips A, Stead M, Velikova G, Brown J, EORTC Quality of Life Group (2007)
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
Eur J Cancer, 43 (11), 1670-8
PubMed 17574838

Galli M, Borrelli G, Jacobsen EM, Marfisi RM, Finazzi G, Marchioli R, Wisloff F, Marziali S, Morboeuf O, Barbui T (2007)
Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study
Blood, 110 (4), 1178-83
PubMed 17440049

Liest°l S, Sandset PM, Mowinckel MC, Wisl°ff F (2007)
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants
J Thromb Haemost, 5 (11), 2204-10
PubMed 17958739

Wisl°ff F (2007)
[Epoetin in cancer treatment--the end of the game?]
Tidsskr Nor Laegeforen, 127 (18), 2359
PubMed 17895937

Publications 2006

Jacobsen EM, Trettenes EJ, Wisl°ff F, Abildgaard U (2006)
Detection and quantification of lupus anticoagulants in plasma from heparin treated patients, using addition of polybrene
Thromb J, 4, 3
PubMed 16436199

Lenhoff S, Hjorth M, Turesson I, Westin J, Gimsing P, Wisl÷ff F, Ahlberg L, Carlson K, Christiansen I, Dahl IM, Forsberg K, Brinch L, Hammerstr÷m J, Johnsen HE, Knudsen LM, Linder O, Mellqvist UH, Nesthus I, Nielsen JL, Nordic Myeloma Study Group (2006)
Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation
Haematologica, 91 (9), 1228-33
PubMed 16956822

Liest°l S, Sandset PM, Jacobsen EM, Mowinckel MC, Wisl°ff F (2006)
Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants
Br J Haematol, 136 (1), 131-7
PubMed 17092306

Smith A, Wisloff F, Samson D, UK Myeloma Forum, Nordic Myeloma Study Group, British Committee for Standards in Haematology (2006)
Guidelines on the diagnosis and management of multiple myeloma 2005
Br J Haematol, 132 (4), 410-51
PubMed 16412016

Wisl°ff F, Kvam AK, Hjorth M, Lenhoff S (2006)
Serum calcium is an independent predictor of quality of life in multiple myeloma
Eur J Haematol, 78 (1), 29-34
PubMed 17038019

Publications 2005

Crowther MA, Wisloff F (2005)
Evidence based treatment of the antiphospholipid syndrome II. Optimal anticoagulant therapy for thrombosis
Thromb Res, 115 (1-2), 3-8
PubMed 15567446

Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J, Baudo F, Berrettini M, Testa S, D'Angelo A, Tognoni G, Barbui T (2005)
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)
J Thromb Haemost, 3 (5), 848-53
PubMed 15869575

Guren TK, Christoffersen T, Thoresen GH, Wisl°ff F, Dajani O, Tveit KM (2005)
[Antineoplastic agents targeting tyrosine kinases]
Tidsskr Nor Laegeforen, 125 (22), 3115-9
PubMed 16299568

Hippe E, Westin J, Wisl÷ff F (2005)
Nordic Myeloma Study Group, the first 15 years: scientific collaboration and improvement of patient care
Eur J Haematol, 74 (3), 185-93
PubMed 15693787

Wisl°ff F, Gulbrandsen N, Hjorth M, Lenhoff S, Fayers P (2005)
Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes
Eur J Haematol, 75 (4), 293-8
PubMed 16146535

Publications 2004

Gulbrandsen N, Hjermstad MJ, Wisl°ff F, Nordic Myeloma Study Group (2004)
Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences
Eur J Haematol, 72 (3), 172-80
PubMed 14962235

Liest°l S, Wisl°ff F (2004)
Effect of subcutaneous administration of dalteparin on lupus anticoagulant assays
Thromb Res, 115 (6), 509-17
PubMed 15792683

Wisl°ff F (2004)
[Total survival as quality indicator]
Tidsskr Nor Laegeforen, 124 (23), 3096; author reply 3096
PubMed 15586201

Wisl°ff F, Crowther M (2004)
Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure
Thromb Res, 114 (2), 75-81
PubMed 15306148

Waage A, Gimsing P, Juliusson G, Turesson I, Gulbrandsen N, Eriksson T, Hjorth M, Nielsen JL, Lenhoff S, Westin J, Wisl÷ff F, Nordic Myeloma Study Group (2004)
Early response predicts thalidomide efficiency in patients with advanced multiple myeloma
Br J Haematol, 125 (2), 149-55
PubMed 15059136

Publications 2003

Hellstr÷m-Lindberg E, Gulbrandsen N, Lindberg G, Ahlgren T, Dahl IM, Dybedal I, Grimfors G, Hesse-Sundin E, Hjorth M, Kanter-Lewensohn L, Linder O, Luthman M, L÷fvenberg E, Oberg G, Porwit-MacDonald A, Rňdlund A, Samuelsson J, Tangen JM, Winquist I, Wisloff F, Scandinavian MDS Group (2003)
A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
Br J Haematol, 120 (6), 1037-46
PubMed 12648074

Iversen PO, Wisl°ff F (2003)
[Gaucher disease]
Tidsskr Nor Laegeforen, 123 (3), 304-7
PubMed 12640894

Wisl°ff F (2003)
[Financing of enzyme treatment in Gaucher disease]
Tidsskr Nor Laegeforen, 123 (3), 364
PubMed 12640908

Wisl°ff F, Brinch L, Hammerstr°m J (2003)
[National guidelines for treatment of chronic myelogenous leukemia]
Tidsskr Nor Laegeforen, 123 (2), 157-9
PubMed 12607495

Publications 2002

Liestol S, Jacobsen EM, Wisloff F (2002)
Dilute prothrombin time-based lupus ratio test - Integrated LA testing with recombinant tissue thromboplastin
Thromb. Res., 105 (2), PII S0049-3848(01)00420-0-182

Liest°l S, Jacobsen EM, Wisl°ff F (2002)
Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin
Thromb Res, 105 (2), 177-82
PubMed 11958810

Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C (2002)
Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor
Blood, 100 (12), 3925-9
PubMed 12393395

Wisl°ff F, Jacobsen EM, Liest°l S (2002)
Laboratory diagnosis of the antiphospholipid syndrome
Thromb Res, 108 (5-6), 263-71
PubMed 12676184

Publications 2001

Gulbrandsen N, Wisl°ff F, Brinch L, Carlson K, Dahl IM, Gimsing P, Hippe E, Hjorth M, Knudsen LM, Lamvik J, Lenhoff S, L°fvenberg E, Nesthus I, Nielsen JL, Turesson I, Westin J, Nordic Myeloma Study Group (2001)
Health-related quality of life in multiple myeloma patients receiving high-dose chemotherapy with autologous blood stem-cell support
Med Oncol, 18 (1), 65-77
PubMed 11778972

Gulbrandsen N, Wisl°ff F, Nord E, Lenhoff S, Hjorth M, Westin J, Nordic Myeloma Study Group (2001)
Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma
Eur J Haematol, 66 (5), 328-36
PubMed 11422413

Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisl°ff F (2001)
The evaluation of clotting times in the laboratory detection of lupus anticoagulants
Thromb Res, 104 (4), 275-82
PubMed 11728529

Wisl°ff F (2001)
[Should iron preparations be available only on prescription?]
Tidsskr Nor Laegeforen, 121 (9), 1155-6
PubMed 11354901

Wisl°ff F (2001)
[Use of blood from patients with hemochromatosis]
Tidsskr Nor Laegeforen, 121 (12), 1448
PubMed 11449762

Wisl°ff F, Tangen JM, Brinch L, Dahl IM, Gruber FX, Hammerstr°m J, Waage A, Nesthus I, Ernst P (2001)
[High dose therapy with autologous stem cell support--finally a progress in myelomatosis]
Tidsskr Nor Laegeforen, 121 (20), 2402-6
PubMed 11603051

Publications 2000

Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisl°ff F (2000)
The Lupus Ratio test--an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants--ISLA 5
Thromb Haemost, 83 (5), 704-8
PubMed 10823266

Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, Wisl÷ff F, Brinch L, Carlson K, Carlsson M, Dahl IM, Gimsing P, Hippe E, Johnsen HE, Lamvik J, L÷fvenberg E, Nesthus I, R÷djer S (2000)
Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group
Blood, 95 (1), 7-11
PubMed 10607678

Wisl°ff F, Gulbrandsen N (2000)
Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group
Acta Oncol, 39 (7), 809-13
PubMed 11145438

Publications 1999

Hjorth M, Holmberg E, R÷djer S, Turesson I, Westin J, Wisl÷ff F (1999)
Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades. Nordic Myeloma Study Group (NMSG)
Eur J Haematol, 62 (4), 271-7
PubMed 10227461

Jacobsen EM, Sandset PM, Wisl°ff F (1999)
Do antiphospholipid antibodies interfere with tissue factor pathway inhibitor?
Thromb Res, 94 (4), 213-20
PubMed 10336236

Ringdal K, Ringdal GI, Kaasa S, Bjordal K, Wisl°ff F, Sundstr°m S, Hjermstad MJ (1999)
Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model
Qual Life Res, 8 (1-2), 25-43
PubMed 10457736

Schjetlein R, Abdelnoor M, Haugen G, Husby H, Sandset PM, Wisl°ff F (1999)
Hemostatic variables as independent predictors for fetal growth retardation in preeclampsia
Acta Obstet Gynecol Scand, 78 (3), 191-7
PubMed 10078579

Stead ML, Brown JM, Velikova G, Kaasa S, Wisl°ff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P (1999)
Development of an EORTC questionnaire module to be used in health-related quality-of-life assessment for patients with multiple myeloma. European Organization for Research and Treatment of Cancer Study Group on Quality of Life
Br J Haematol, 104 (3), 605-11
PubMed 10086801

Turesson I, Abildgaard N, Ahlgren T, Dahl I, Holmberg E, Hjorth M, Nielsen JL, OdÚn A, Seidel C, Waage A, Westin J, Wisl÷ff F (1999)
Prognostic evaluation in multiple myeloma: an analysis of the impact of new prognostic factors
Br J Haematol, 106 (4), 1005-12
PubMed 10520004

Wisl°ff F, Gulbrandsen N, Nord E (1999)
Therapeutic options in the treatment of multiple myeloma: pharmacoeconomic and quality-of-life considerations
Pharmacoeconomics, 16 (4), 329-41
PubMed 10623362

Wisl°ff F, Kierulf P (1999)
[An anemia: without blood]
Tidsskr Nor Laegeforen, 119 (19), 2801
PubMed 10494197

Publications 1998

Foss Haug KB, Kierulf P, Sandset PM, Urdal P, Wisl°ff F (1998)
[Hereditary hemochromatosis and use of genetic tests]
Tidsskr Nor Laegeforen, 118 (12), 1911
PubMed 9638063

Kaasa S, Hjermstad MJ, Jordh°y MS, Wisl°ff F, Loge JH (1998)
Compliance in quality of life data: a Norwegian experience
Stat Med, 17 (5-7), 623-32
PubMed 9549811

Schjetlein R, Haugen G, Moe N, Husby H, Wisloff F (1998)
Preeclampsia and fetal growth retardation: Is there an association with antiphospholipid antibodies?
Hypertens. Pregnancy, 17 (1), 81-92

Wisl°ff F (1998)
[Quality assurance in diagnosis and treatment of hematologic diseases]
Tidsskr Nor Laegeforen, 118 (2), 209
PubMed 9485610

Publications 1997

Bach-Gansmo ET, Strand O, Godal HC, Wisl°ff F, Skj°nsberg OH (1997)
Discrepancy between latex and ELISA D-dimer values in sepsis may be caused by human neutrophil elastase
Thromb Res, 86 (2), 141-52
PubMed 9175235

Djurovic S, Schjetlein R, Wisl°ff F, Haugen G, Berg K (1997)
Increased levels of intercellular adhesion molecules and vascular cell adhesion molecules in pre-eclampsia
Br J Obstet Gynaecol, 104 (4), 466-70
PubMed 9141584

Djurovic S, Schjetlein R, Wisl°ff F, Haugen G, Husby H, Berg K (1997)
Plasma concentrations of Lp(a) lipoprotein and TGF-beta1 are altered in preeclampsia
Clin Genet, 52 (5), 371-6
PubMed 9520129

Jacobsen EM, Wisl°ff F (1997)
A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies
Thromb Res, 86 (5), 385-91
PubMed 9211629

Nord E, Wisl°ff F, Hjorth M, Westin J (1997)
Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial
Pharmacoeconomics, 12 (1), 89-103
PubMed 10169390

Schjetlein R, Haugen G, Sandset PM, Wisl°ff F (1997)
Reduced C4b-binding protein in preeclampsia
Thromb Res, 85 (2), 153-8
PubMed 9058489

Schjetlein R, Haugen G, Wisl°ff F (1997)
Markers of intravascular coagulation and fibrinolysis in preeclampsia: association with intrauterine growth retardation
Acta Obstet Gynecol Scand, 76 (6), 541-6
PubMed 9246959

Tangen JM, Abdelnoor M, Brinch L, Dahl IM, Lamvik J, Ly B, Nesthus I, Wisl°ff F (1997)
Survival in 86 patients, aged 15-60, with primary acute myelogenous leukemia, treated with a common program in the Norwegian health regions I, III, IV and V in the period 1990-1995
Eur J Haematol, 59 (2), 110-4
PubMed 9293859

Wisl°ff F (1997)
[Measurement of health-related quality of life in malignant diseases. Does it have any consequences?]
Tidsskr Nor Laegeforen, 117 (26), 3812-6
PubMed 9417687

Wisl°ff F, Hjorth M (1997)
Health-related quality of life assessed before and during chemotherapy predicts for survival in multiple myeloma. Nordic Myeloma Study Group
Br J Haematol, 97 (1), 29-37
PubMed 9136939

Publications 1996

Hjorth M, Westin J, Dahl IMS, Gimsing P, Hippe E, Holmberg E, Lamvik J, Nielsen JL, Lofvenberg E, Palva IP, Rodjer S, Talstad I, Turesson I, Wisloff F, Zador G, AmslerNordin S, Polgary M, Oden A, Wallgren A, Wilhelmsen L, Hellqvist L, Hasselblom S, Carneskog J, Lindqvist O, Hoffman P et al. (1996)
Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma - A randomized, controlled trial
Ann. Intern. Med., 124 (2), 212-&

Jacobsen EM, Sandset PM, Wisl°ff F (1996)
Lupus anticoagulant and a functional assay for tissue factor pathway inhibitor
Thromb Res, 83 (4), 339-40
PubMed 8870178

Jacobsen EM, Wisl°ff F (1996)
False negative screening tests for lupus anticoagulants--an unrecognized problem?
Thromb Res, 82 (5), 445-51
PubMed 8771705

Sletnes KE, Holte H, Halvorsen S, Jakobsen E, Wisl°ff F, Kval°y S (1996)
Activation of coagulation and deep vein thrombosis after bone marrow harvesting and insertion of a Hickman-catheter in ABMT patients with malignant lymphoma
Bone Marrow Transplant, 17 (4), 577-81
PubMed 8722358

Wisl°ff F, Eika S, Hippe E, Hjorth M, Holmberg E, Kaasa S, Palva I, Westin J (1996)
Measurement of health-related quality of life in multiple myeloma. Nordic Myeloma Study Group
Br J Haematol, 92 (3), 604-13
PubMed 8616024

Wisl°ff F, Hjorth M, Kaasa S, Westin J (1996)
Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group
Br J Haematol, 94 (2), 324-32
PubMed 8759893

Waage A, Dahl IM, Evensen SA, Holte H, Lamvik J, Sletnes K, Wisl°ff F (1996)
[Treatment with growth factors and cytokines in hematologic diseases]
Tidsskr Nor Laegeforen, 116 (12), 1465-9
PubMed 8650635

Publications 1995

Jacobsen EM, Wisl°ff F, Finset A (1995)
[Does social support have an impact on the prognosis in cancer?]
Tidsskr Nor Laegeforen, 115 (24), 3022-5
PubMed 7570530

Schjetlein R, Wisl°ff F (1995)
An evaluation of two commercial test procedures for the detection of lupus anticoagulant
Am J Clin Pathol, 103 (1), 108-11
PubMed 7817935

Schjetlein R, Wisl°ff F (1995)
Detection of lupus anticoagulant: an evaluation of routines for preparation and storage of plasma
Thromb Res, 79 (1), 135-40
PubMed 7495101

Sletnes KE, Godal HC, Wisl°ff F (1995)
Disseminated intravascular coagulation (DIC) in adult patients with acute leukaemia
Eur J Haematol, 54 (1), 34-8
PubMed 7859873

Publications 1994

Evensen SA, Brinch L, Tj°nnfjord G, Stavem P, Wisl°ff F (1994)
Estimated 8-year survival of more than 40% in a population-based study of 79 adult patients with acute lymphoblastic leukaemia
Br J Haematol, 88 (1), 88-93
PubMed 7803261

Wisl°ff F, Brinch L, Bruserud O, Dahl IM, Lamvik J (1994)
[High-dose therapy with autologous stem cell support in malignant diseases]
Tidsskr Nor Laegeforen, 114 (26), 3115
PubMed 7974434

Wisl°ff F, Brinch L, Bruserud O, Dahl IM, Lamvik J (1994)
[Treatment with high-dose cytostatic agents]
Tidsskr Nor Laegeforen, 114 (26), 3115-6
PubMed 7974435

Publications 1993

Schjetlein R, Sletnes KE, Wisl°ff F (1993)
A quantitative, semi-automated and computer-assisted test for lupus anticoagulant
Thromb Res, 69 (2), 239-50
PubMed 8446953

Schjetlein R, Wisl°ff F (1993)
Choice of standard plasma for diagnosis and quantitation of lupus anticoagulants
Thromb Res, 72 (4), 287-94
PubMed 8303668

Wisl°ff F, Sletnes KE, Schjetlein R (1993)
[Phospholipid antibodies (lupus anticoagulant and cardiolipin antibodies). Detection and clinical significance]
Tidsskr Nor Laegeforen, 113 (18), 2269-72
PubMed 8362396

Publications 1992

Evensen SA, Brinch L, Wisl°ff F, Talstad I, Waage A, Dahl IM (1992)
[Recommendation to uncritical use of granulocyte colony-stimulating factor (G-CSF)?]
Tidsskr Nor Laegeforen, 112 (24), 3122
PubMed 1281932

Sletnes KE, Gravem K, Wisl°ff F (1992)
Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies
Thromb Res, 66 (1), 43-53
PubMed 1412182

Lancet, 340 (8811), 117-118

Sletnes KE, Smith P, Abdelnoor M, Arnesen H, Wisl°ff F (1992)
Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke
Lancet, 339 (8791), 451-3
PubMed 1346819

Sletnes KE, Wisl°ff F, Moe N, Dale PO (1992)
Antiphospholipid antibodies in pre-eclamptic women: relation to growth retardation and neonatal outcome
Acta Obstet Gynecol Scand, 71 (2), 112-7
PubMed 1316037

Wisl°ff F, Gimsing P, Hedenus M, Hippe E, Palva I, Talstad I, Turesson I, Westin J (1992)
Bolus therapy with mitoxantrone and vincristine in combination with high-dose prednisone (NOP-bolus) in resistant multiple myeloma. Nordic Myeloma Study Group (NMSG)
Eur J Haematol, 48 (2), 70-4
PubMed 1547878

Publications 1991

Wisl°ff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad K, Gr°nvold T, Holm B, L°vňsen K, Tj°nnfjord GE (1991)
Incidence and follow-up of asymptomatic multiple myeloma. The myeloma project of health region I in Norway. II
Eur J Haematol, 47 (5), 338-41
PubMed 1761119

Wisl°ff F, Andersen P, Andersson TR, Brandt E, Eika C, Fjaestad K, Ly B, L°vňsen K, Str°m BR, Tj°nnfjord GE (1991)
Has the incidence of multiple myeloma in old age been underestimated? The myeloma project of health region I in Norway. I
Eur J Haematol, 47 (5), 333-7
PubMed 1761118

Wisl°ff F, Sletnes KE, Michaelsen T (1991)
Shared idiotypic determinant in mono- and polyclonal anti-phospholipid antibodies with lupus anticoagulant activity
Thromb Res, 61 (3), 201-11
PubMed 1902996

Publications 1990

Skj°nsberg OH, Wisl°ff F, Godal HC (1990)
Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal IgM antibody expressing lupus anticoagulant activity
Thromb Res, 58 (3), 349-52
PubMed 2112789

Sletnes KE, Keirung G, Wisl°ff F (1990)
Quantitation of anticephalin antibodies in a computer-assisted enzyme-linked immunosorbent assay (ELISA): relation to lupus anticoagulant
Thromb Res, 57 (2), 235-46
PubMed 2107590

Sletnes KE, Larsen EW, Stokland O, Wisl°ff F (1990)
Antiphospholipid antibodies detected as anticephalin and anticardiolipin antibodies in patients with acute myocardial infarction: immunological response to myocardial necrosis?
Thromb Res, 59 (3), 675-80
PubMed 2237834

Wisl°ff F, Sletnes K, Godal HC (1990)
[Antiphospholipid syndrome and lupus anticoagulant]
Tidsskr Nor Laegeforen, 110 (1), 94
PubMed 2300947

Publications 1989

Evensen SA, Brinch L, Wisl°ff F (1989)
[Recurrence or therapeutic resistance of acute myelogenous leukemia. Effect of mitoxantrone and cytosine arabinoside]
Tidsskr Nor Laegeforen, 109 (19-21), 2004-6
PubMed 2749689

Sletnes KE, Wisl°ff F, Schlichting E, Kňresen R (1989)
[Splenectomy in hematologic diseases]
Tidsskr Nor Laegeforen, 109 (2), 201-3
PubMed 2916199

Publications 1987

Evensen SA, Wisl°ff F, MŘller E, Talstad I, Waage A, Johansen L (1987)
Aclarubicin in the treatment of relapsed or resistant acute myelogenous leukaemia: a phase II trial
Eur J Haematol Suppl, 47, 43-7
PubMed 3471524

Wisl°ff F, Godal HC, Gaarder PI, Langebrekke A (1987)
[Lupus anticoagulant. Coagulation inhibitor associated with thrombosis tendency]
Tidsskr Nor Laegeforen, 107 (13), 1128-30
PubMed 3111007

Wisl°ff F, Michaelsen TE, Godal HC (1987)
Monoclonal IgM with lupus anticoagulant activity in a case of Waldenstr÷m's macroglobulinaemia
Eur J Haematol, 38 (5), 456-60
PubMed 3115822

Publications 1985

Pillgram-Larsen J, Wisl°ff F, J°rgensen JJ, Godal HC, Semb G (1985)
Effect of high-dose ampicillin and cloxacillin on bleeding time and bleeding in open-heart surgery
Scand J Thorac Cardiovasc Surg, 19 (1), 45-8
PubMed 4012240

Wisl°ff F, Godal HC (1985)
[Severe aplastic anemia in adults. Therapeutic progress]
Tidsskr Nor Laegeforen, 105 (14), 966-8
PubMed 3892767

Wisl°ff F, Godal HC (1985)
Cyclosporine in refractory severe aplastic anemia
N Engl J Med, 312 (18), 1193
PubMed 3982483

Wisl°ff F, Michaelsen TE, Kierulf P, Godal HC (1985)
The molecular localization of the ability of certain monoclonal immunoglobulins to interfere with fibrin polymerization
Thromb Res, 40 (4), 473-82
PubMed 4082120

Publications 1984

Kj°lseth I, Wisl°ff F, Godal HC (1984)
[Combination chemotherapy in Alkeran-resistant myelomatosis]
Tidsskr Nor Laegeforen, 104 (13), 873-4
PubMed 6463973

Wisl°ff F, Godal HC, Kierulf P (1984)
[Diagnosis of hemoglobinopathies and thalassemia]
Tidsskr Nor Laegeforen, 104 (28), 1952-5
PubMed 6495285

Wisl°ff F, Michaelsen TE, Godal HC (1984)
Inhibition or acceleration of fibrin polymerization by monoclonal immunoglobulins and immunoglobulin fragments
Thromb Res, 35 (1), 81-90
PubMed 6474410

Publications 1983

SCAND J HAEMATOL, 30 39, 31-32

J. Clin. Immunol., 3 (3), 212-221

Kval°y S, Lindmo T, Davies C, Wisl°ff F, Godal T (1983)
SÚzary cells with an unusual phenotype, their modulation with 12-O-tetradecanoyl phorbol-13-acetate (TPA) in vitro, and their relationship to T-cell development
J Clin Immunol, 3 (3), 212-21
PubMed 6604064

Nilsen DW, Wisl°ff F, Gjesdal KT (1983)
[Thermography in thrombosis. Used as a screening method in patients with suspected deep vein thrombosis]
Tidsskr Nor Laegeforen, 103 (6), 592-4
PubMed 6868033

SCAND J HAEMATOL, 30 39, 19-21

Wisl°ff F, Larsen JP, Dahle A, Lie M, Godal HC (1983)
Effect of prophylactic high-dose treatment with ampicillin and cloxacillin on bleeding time and bleeding in patients undergoing elective vascular surgery
Scand J Haematol, 31 (2), 97-101
PubMed 6612231

Publications 1982

Br. J. Surg., 69 (1), 52-54

Wisl°ff F, Godal HC (1982)
[Qualitative defects of blood platelets in clinical practice]
Tidsskr Nor Laegeforen, 102 (15), 842-5
PubMed 7157261

Wisl°ff F, Osnes M, Jakobsen J (1982)
[Chronic pancreatitis as a cause to extrahepatic cholestasis]
Tidsskr Nor Laegeforen, 102 (26), 1325-7
PubMed 7164078

Publications 1981

Eika C, Godal HC, Kierulf P, Tjora S, Wisl°ff F (1981)
[Is serum ferritin of any use in the diagnosis of iron deficiency?]
Tidsskr Nor Laegeforen, 101 (22), 1177-9
PubMed 7281142

Rutlin E, Wisl°ff F, Myren J, Serck-Hanssen A (1981)
Intestinal telangiectasis in Turner's syndrome
Endoscopy, 13 (2), 86-7
PubMed 6971752

Wisl°ff F, Godal HC (1981)
Prolonged bleeding time with adequate platelet count in hospital patients
Scand J Haematol, 27 (1), 45-50
PubMed 7336158

Publications 1980

Wisl°ff F, Bull-Berg J, Myren J (1980)
Gastric involvement in herpes zoster
Endoscopy, 12 (3), 134-5
PubMed 7379763

Wisl°ff F, Magnus EM (1980)
[Hematological complications of alcohol abuse]
Tidsskr Nor Laegeforen, 100 (24), 1433-5
PubMed 7444888

Publications 1979

Acta Med. Scand., 205 (3), 237-242

Wisl÷ff F, Boman D (1979)
Acquired stomatocytosis in alcoholic liver disease
Scand J Haematol, 23 (1), 43-50
PubMed 493871

Wisl÷ff F, Boman D (1979)
Haemolytic anaemia in alcohol abuse. A review of 14 cases
Acta Med Scand, 205 (3), 237-42
PubMed 425850

Wisl°ff F, Bull-Berg J, Myren J (1979)
Herpes zoster of the stomach
Lancet, 2 (8149), 953
PubMed 91038

Publications 1978

Wisl÷ff F (1978)
Schoolteachers and health in developing countries
Lancet, 2 (8088), 527
PubMed 79895

Publications 1977

Wisloff F, Christoffersen T (1977)
Role of cyclic nucleotides in human lymphocyte-mediated antibody-dependent cytotoxicity
Int Arch Allergy Appl Immunol, 53 (1), 42-9
PubMed 190171

Publications 1976

Froland SS, Wisloff F, Stavem P (1976)
Abnormal lymphocyte populations in pure red cell aplasia
Scand J Haematol, 17 (4), 241-50
PubMed 1087044

Publications 1975

Froland SS, Natvig JB, Wisloff F (1975)
Lymphocyte subpopulations in rheumatoid arthritis
Rheumatology, 6, 231-41
PubMed 1081728

Froland SS, Wisloff F (1975)
[Identification and characterization of a 3rd population of human lymphocytes with receptors for IgG (Fc-receptors)]
Medicina (B Aires), 35 (4), 355-68
PubMed 1196111

Hoyeraal HM, Froland SS, Wisloff F (1975)
Lymphocyte populations and cellular immune reactions in juvenile rheumatoid arthritis
Scand J Immunol, 4 (8), 801-10
PubMed 1082632

Michaelsen TE, Wisloff F, Natvig JB (1975)
Structural requirements in the Fc region of rabbit IgG antibodies necessary to induce cytotoxicity by human lymphocytes
Scand J Immunol, 4 (1), 71-8
PubMed 1079629

Scand. J. Rheumatol., 5 12, 77-88

Natvig JB, Abrahamsen T, Anders R, Froland SS, Husby G, Hoyeraal HM, Kňss E, Mellbye OJ, Munthe E, Pahle J, Wisloff F (1975)
Lymphocyte subpopulations and immune reactions in rheumatoid inflammatory tissues
Scand J Rheumatol Suppl, 12, 77-88
PubMed 1084571

Natvig JB, Froland SS, Wisloff F, Munthe E (1975)
Different lymphocyte populations in rheumatoid arthritis and their relationship to anti-Ig activities
Ann Clin Res, 7 (3), 146-53
PubMed 1081361

Wisl°ff F, Fr°land SS, Natvig JB (1975)
Deficient lymphoid cell-mediated, PHA-induced cytotoxicity in rheumatoid arthritis patients
Scand J Immunol, 4 (3), 303-7
PubMed 1080292

Publications 1974

Froland SS, Michaelsen TE, Wisloff F, Natvig JB (1974)
Specificity of receptors for IgG on human lymphocyte-like cells
Scand J Immunol, 3 (4), 509-17
PubMed 4137203

Froland SS, Wisloff F, Michaelsen TE (1974)
Human lymphocytes with receptors for IgG. A population of cells distinct from T- and B-lymphocytes
Int Arch Allergy Appl Immunol, 47 (1), 124-38
PubMed 4546531

ACTA PATH MICRO IM B, B 82 (2), 263-269

Wisloff F, Froland SS, Engeset A (1974)
Selective defects of in vitro parameters of lymphoid cell function in patients with irradiated testicular tumour and in patients with lymphoproliferative disorders
Acta Pathol Microbiol Scand B Microbiol Immunol, 82 (2), 263-9
PubMed 4546906

Wisloff F, Froland SS, Michaelsen TE (1974)
Antibody-dependent cytotoxicity mediated by human Fc-receptor-bearing cells lacking markers for B- and T-lymphocytes
Int Arch Allergy Appl Immunol, 47 (1), 139-54
PubMed 4603056

Wisloff F, Froland SS, Michaelsen TE (1974)
Characterization of subpopulations of human lymphoid cells participating in phytohemagglutinin and concanavalin A-induced cytotoxicity
Int Arch Allergy Appl Immunol, 47 (4), 488-97
PubMed 4547156

Wisloff F, Michaelsen TE, Froland SS (1974)
Inhibition of antibody-dependent human lymphocyte-mediated cytotoxicity by immunoglobulin classes, IgG subclasses, and IgG fragments
Scand J Immunol, 3 (1), 29-38
PubMed 4857243

Publications 1973

Solem JH, Tolňs P, Wisloff F (1973)
[Follow-up study of patients treated surgically for non-toxic goiter and thyrotoxicosis. A 1O year material]
Tidsskr Nor Laegeforen, 93 (16), 1223-5
PubMed 4800553

Wisloff F, Froland SS (1973)
Antibody-dependent lymphocyte-mediated cytotoxicity in man: no requirement for lymphocytes with membrane-bound immunoglobulin
Scand J Immunol, 2 (2), 151-7
PubMed 4542262

INT ARCH ALLER A IMM, 45 (3), 456-466

Wisl÷ff F, Fr÷land SS (1973)
Studies on the cytotoxic activity of human lymphoid cells activated by concanavalin A
Int Arch Allergy Appl Immunol, 45 (3), 456-66
PubMed 4542732

Publications 1969

Stavem P, Jeremic M, Hjort PF, Wisl÷ff F, Vogt E, Oyen R, Abrahamsen AF, S÷vde A (1969)
Hereditary thrombocytopenia with excessively prolonged bleeding time
Scand J Haematol, 6 (4), 250-61
PubMed 5348279